德诚资本
| 机构性质： | VC,VC-PE,天使投资 |
| 办公地址： | |
| 联系方式： | 请先上传投递商业计划，项目免费直达该资方约谈-->> |
| 投资行业： | 医疗健康、生物科技
|
| 投资阶段： | 产品开发,上线初期,增长期 |
Dr. Tony Tong is a Vice President of Decheng Capital and has been with the firm since May 2014. He has an interest in diverse sectors within the China healthcare industry. He currently serves on the boards of CardiMED and Insight Lifetech. Prior to joining Decheng Capital, Dr. Tong was a Vice President at Mingly China Growth Fund (MCGF), focusing on evaluating investment opportunities in the healthcare sector and serving on the boards of Yocaly (acquired by Lepu Medical), Family of Health (partially acquired by Sunshine Insurance), Sonicmed and Baifendian Technology. From 2009 to 2012, Dr. Tong was Senior Investment Associate at Yifang Ventures, a venture capital investment and asset management firm founded by Dr. Eric Xu, the Co-founder of Baidu.com. Dr. Tong received his PhD in Biochemistry and Molecular Biology from Institute of Biophysics of Chinese Academy of Science, a BS degree in Life Science from University of Science and Technology of China and the second BS degree in Economics from Peking University.
项目需求点击详情
Dr. Nick Pliam is a Principal at Decheng Capital. He has been with the firm since its inception and Bay City Capital since 2005. Dr. Pliam is trained as a cell biologist and orthopedic surgeon, and has worked within, and as an advisor to, biopharmaceutical and medical technology companies. He is a founder of Guided Delivery Systems, a medical device company developing a minimally invasive technology for treatment of mitral valve regurgitation, and a founder of Pharmagenesis, a natural products pharmaceutical company. As an independent consultant and as managing director of a boutique investment banking firm, he has advised life science companies and investors (including Biomet, Devax, Hanwha Pharmaceutical, Marubeni Group, Micrus Endovascular, and Triage Medical) on financing transactions and strategy. He is an inventor with patents in medical devices and biopharmaceuticals. Dr. Pliam serves on the boards of directors of Nevro Corporation (NYSE: NVRO) and a former member of the board of IDev Technologies (acquired by Abbott Laboratories). He holds an MD from Dartmouth Medical School and a PhD in Endocrine Physiology from the University of California, San Francisco. Dr. Pliam completed his surgical training at UCSF and Stanford University. He completed his undergraduate degree in German literature from the University of California, Berkeley, and studied at Georg August Universitaet in Goettingen.
项目需求点击详情
Dr. Qiang Xu is a Principal at Decheng Capital and has been with the firm since its inception. He is currently serving on the boards of BCFoods and GYT HealthCare Services. He has over 14 years of experience from biotechnology start-ups to pharmaceutical companies and also has extensive experience in agricultural biotechnology. He was most recently Vice President of Research at Osel and the principal investigator for multiple grants funded by the NIH and other foundations. Dr. Xu started his biotechnology career at Bayer, worked at Pan Pacific Pharmaceuticals as a director, and Scios as a member of the Alzheimers Disease Discovery Program. He has published over 30 peer reviewed papers, and 50 conference presentations, and is the co-inventor of 10 patents or applications. Dr. Xu received his BS in agronomy and MS in Crop Sciences (with Professor Yu Songlie, an academician of the Chinese Academy of Engineering) and PhD in plant physiology from Kansas State University. He completed his postdoctoral training at the University of California, Berkeley.
项目需求点击详情
Mr. Victor E. Tong, Jr. is a Partner at Decheng Capital and has been with the firm since its inception. At Decheng, Mr. Tong focuses on investments in biotechnology and medical technology companies in China and US. Mr. Tong currently serves on the boards of AccuraGen, EpimAb Biotherapeutics, GenapSys, GeneMDx, Levitas, ReadCoor and SentreHeart. He previously served on the boards of past Decheng companies Cirina (acquired by GRAIL) and GeneWEAVE Biosciences (acquired by Roche). Mr. Tong’s investment portfolio also includes 3SBio (1530.HK), Apexigen, ARMO Biosciences, Cellular Research (acquired by Becton Dickinson), China Biologic Products (NASDAQ: CBPO), Hummingbird Bioscience, Invitae (NASDAQ: NVTA) and SINOMED. Prior to joining Decheng, Mr. Tong was a Principal at Bay City Capital and was a member of the founding team of Nevro (NYSE: NVRO), a Bay City Capital-originated medical device company. He also played a key role in the firm’s investments in Cadence Pharmaceuticals (acquired by Mallinckrodt), GenturaDx (acquired by Luminex), Ion Torrent Systems (acquired by Life Technologies) and NextWave Pharmaceuticals (acquired by Pfizer). Prior to joining Bay City, Mr. Tong was an investment banker with Morgan Stanley, where he advised healthcare companies on initial public offerings and specialized in strategic advisory work. Prior to Morgan Stanley, Mr. Tong was an entrepreneur at Hana Biosciences (acquired by Spectrum Pharmaceuticals), where he was responsible for pipeline development, licensing and product launch for cancer products. Mr. Tong began his career participating in The Human Genome Project and its race to sequence the human genome as a research assistant at Incyte in 1999. Mr. Tong is a graduate of the University of California, Berkeley, where he earned a BA degree in Molecular and Cell Biology and a BS degree in Business Administration from the Haas School of Business.
项目需求点击详情
微信公众号
